Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LINNEA I CHAP

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1700839362
CMS profile
77578
Location
BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$55,329.76

139 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LINNEA I CHAP

NPI 1700839362 · CMS profile ID 77578

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BEVERLY HILLS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700839362?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LINNEA I CHAP, NPI 1700839362, CMS profile ID 77578. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700839362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). LINNEA I CHAP, NPI 1700839362, CMS profile ID 77578. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700839362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
LINNEA I CHAP, NPI 1700839362, CMS profile ID 77578, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1700839362?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

139 matching records · $55,329.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 139 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–139 of 139.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $19.7505/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789069231 CMS
PFIZER INC. $1,500.0005/14/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833394103 CMS
Merck Sharp & Dohme Corporation $19.0505/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848677503 CMS
Merck Sharp & Dohme Corporation $24.6905/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848706895 CMS
Genentech USA, Inc. $23.2505/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835941793 CMS
AstraZeneca Pharmaceuticals LP $12.1605/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829540055 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.2505/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789079621 CMS
JAZZ PHARMACEUTICALS INC. $19.8705/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845589609 CMS
GENZYME CORPORATION $13.3704/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843464835 CMS
Amgen Inc. $25.6404/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825557717 CMS
PUMA BIOTECHNOLOGY, INC. $25.0004/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834086013 CMS
AstraZeneca Pharmaceuticals LP $24.0004/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830095231 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.0004/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789149119 CMS
Daiichi Sankyo Inc. $25.0004/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836281165 CMS
Gilead Sciences, Inc. $26.5404/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848174645 CMS
Genentech USA, Inc. $22.0003/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835941753 CMS
Exelixis Inc. $30.3803/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838867541 CMS
PUMA BIOTECHNOLOGY, INC. $24.3903/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834086293 CMS
Amgen Inc. $25.6403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825557713 CMS
AstraZeneca Pharmaceuticals LP $21.2503/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829783363 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.0303/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789057575 CMS
Pharmacyclics LLC, An AbbVie Company $20.8403/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781008817 CMS
Acrotech Biopharma LLC $15.0003/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855378813 CMS
Genentech USA, Inc. $19.5303/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835941791 CMS
MACROGENICS, INC. $1,500.0003/03/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833897687 CMS
AstraZeneca Pharmaceuticals LP $24.0002/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829560191 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.0002/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789064683 CMS
PUMA BIOTECHNOLOGY, INC. $29.8502/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834094251 CMS
GENZYME CORPORATION $12.4902/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843464831 CMS
Genentech USA, Inc. $24.3802/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835941787 CMS
Genentech USA, Inc. $22.0002/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835941773 CMS
Pharmacyclics LLC, An AbbVie Company $21.0401/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781008815 CMS
PUMA BIOTECHNOLOGY, INC. $24.4001/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834092463 CMS
AstraZeneca Pharmaceuticals LP $25.0001/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829576357 CMS
JAZZ PHARMACEUTICALS INC. $22.0801/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845577339 CMS
Exelixis Inc. $27.9101/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838865985 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.7501/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789194295 CMS
Genentech USA, Inc. $19.4401/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835941783 CMS
BeiGene USA, Inc. $33.6001/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846699339 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $86,107.55 306
PY2020 $30,447.49 82
PY2021 $55,329.76 139
PY2022 $117,610.16 241
PY2023 $168,561.21 233
PY2024 $163,655.28 227
PY2025 $85,177.62 222

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,002,595.80 174
PY2024 Principal investigator $713,766.70 102
PY2023 Recipient $300.00 1
PY2023 Principal investigator $117,471.27 9
PY2022 Recipient $450.00 1
PY2022 Principal investigator $936,160.90 31
PY2021 Principal investigator $1,175,372.54 30
PY2020 Recipient $1,068.14 2
PY2020 Principal investigator $856,898.96 10
PY2019 Recipient $6,415.35 2
PY2019 Principal investigator $477,327.84 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

174 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $111,014.15 12/31/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow No dispute reported 06/30/2026 1232924246
Principal investigator 1 Genentech, Inc. $7,440.00 12/19/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579363
Principal investigator 1 Genentech, Inc. $690.00 12/19/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579366
Principal investigator 1 Genentech, Inc. $10,880.00 12/19/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579369
Principal investigator 1 BioNTech SE $195.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249017873
Principal investigator 1 BioNTech SE $195.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249017875
Principal investigator 1 BioNTech SE $1,857.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249017877
Principal investigator 1 BioNTech SE $1,857.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249017879
Principal investigator 1 BioNTech SE $1,857.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249017881
Principal investigator 1 BioNTech SE $1,857.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249017883
Principal investigator 1 BioNTech SE $98.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018073
Principal investigator 1 BioNTech SE $98.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018075
Principal investigator 1 BioNTech SE $98.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018077
Principal investigator 1 BioNTech SE $98.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018079
Principal investigator 1 BioNTech SE $165.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018081
Principal investigator 1 BioNTech SE $165.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018083
Principal investigator 1 BioNTech SE $165.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018085
Principal investigator 1 BioNTech SE $165.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018087
Principal investigator 1 BioNTech SE $195.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018089
Principal investigator 1 BioNTech SE $195.00 11/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327 No dispute reported 06/30/2026 1249018091
Principal investigator 1 Genentech, Inc. $232.00 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579320
Principal investigator 1 Genentech, Inc. $10,350.00 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579325
Principal investigator 1 Genentech, Inc. $300.84 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579329
Principal investigator 1 Genentech, Inc. $232.00 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579332
Principal investigator 1 Genentech, Inc. $7,547.30 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579337
Principal investigator 1 Genentech, Inc. $52.00 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579341
Principal investigator 1 Genentech, Inc. $169.00 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579346
Principal investigator 1 Genentech, Inc. $311.00 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579351
Principal investigator 1 Genentech, Inc. $255.00 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579355
Principal investigator 1 Genentech, Inc. $311.00 10/29/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579358
Principal investigator 1 Novartis Pharmaceuticals Corporation $111.72 10/28/2025 Non-covered Recipient Entity
BEVERLY HILLS CANCER CENTER
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190307251
Principal investigator 1 Genentech, Inc. $232.00 09/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579252
Principal investigator 1 Genentech, Inc. $311.00 09/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579257
Principal investigator 1 Genentech, Inc. $424.00 09/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579301
Principal investigator 1 Genentech, Inc. $86.00 08/26/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579248
Principal investigator 1 BioNTech SE $74.00 08/25/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center & Optima Diagnostic Imaging
BNT323-03 No dispute reported 06/30/2026 1249017486
Principal investigator 1 Genentech, Inc. $232.00 08/21/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579261
Principal investigator 1 Genentech, Inc. $104.00 08/21/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579265
Principal investigator 1 Genentech, Inc. $938.50 08/21/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579271
Principal investigator 1 Genentech, Inc. $415.00 08/21/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579280
Principal investigator 1 PFIZER INC. $7,750.00 07/19/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER ADVANCED OR METASTATIC BREAST CANCER SUBSTUDY C ARV471 IN COMBINATION WITH SAMURACICLIB No dispute reported 06/30/2026 1228782689
Principal investigator 1 BioNTech SE $420.00 07/09/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center & Optima Diagnostic Imaging
BNT323-03 No dispute reported 06/30/2026 1249017484
Principal investigator 1 Genentech, Inc. $424.00 07/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579276
Principal investigator 1 Genentech, Inc. $311.00 07/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579282
Principal investigator 1 Genentech, Inc. $208.00 07/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579286
Principal investigator 1 Genentech, Inc. $10,880.00 07/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579292
Principal investigator 1 Genentech, Inc. $232.00 07/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579296
Principal investigator 1 Genentech, Inc. $690.00 07/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579304
Principal investigator 1 Genentech, Inc. $277.00 07/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579307
Principal investigator 1 Genentech, Inc. $232.00 07/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579311
Principal investigator 1 Genentech, Inc. $311.00 07/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579317
Principal investigator 1 BioNTech SE $97.00 07/01/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center & Optima Diagnostic Imaging
BNT327-02 No dispute reported 06/30/2026 1249017482
Principal investigator 1 BioNTech SE $97.00 07/01/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center & Optima Diagnostic Imaging
BNT327-02 No dispute reported 06/30/2026 1249017502
Principal investigator 1 PFIZER INC. $6,875.00 06/26/2025 Non-covered Recipient Entity
Beverly Hills Oncology Medical Group Inc
TACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER ADVANCED OR METASTATIC BREAST CANCER SUBSTUDY C ARV471 IN COMBINATION WITH SAMURACICLIB No dispute reported 06/30/2026 1228789942
Principal investigator 1 Genentech, Inc. $1,860.00 06/12/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579209
Principal investigator 1 BioNTech SE $336.00 05/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018015
Principal investigator 1 BioNTech SE $1,784.00 05/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018017
Principal investigator 1 BioNTech SE $195.00 05/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018019
Principal investigator 1 BioNTech SE $336.00 05/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018049
Principal investigator 1 BioNTech SE $1,784.00 05/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018051
Principal investigator 1 BioNTech SE $195.00 05/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018053
Principal investigator 1 BioNTech SE $336.00 05/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018055
Principal investigator 1 BioNTech SE $1,784.00 05/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018057
Principal investigator 1 BioNTech SE $195.00 05/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018059
Principal investigator 1 Genentech, Inc. $3,720.00 05/08/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579238
Principal investigator 1 BioNTech SE $97.00 05/01/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center & Optima Diagnostic Imaging
BNT327-02 No dispute reported 06/30/2026 1249017480
Principal investigator 1 BioNTech SE $97.00 05/01/2025 Non-covered Recipient Entity
Beverly Hills Cancer Center & Optima Diagnostic Imaging
BNT327-02 No dispute reported 06/30/2026 1249017500
Principal investigator 1 Eli Lilly and Company $1,492.00 04/29/2025 Non-covered Recipient Entity
BEVERLY HILLS CANCER CENTER
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187881250
Principal investigator 1 Genentech, Inc. $311.00 04/28/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579234
Principal investigator 1 Genentech, Inc. $348.00 04/28/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579241
Principal investigator 1 Genentech, Inc. $424.00 04/28/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579245
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,592.48 04/25/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185542436
Principal investigator 1 BioNTech SE $336.00 04/22/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018021
Principal investigator 1 BioNTech SE $1,784.00 04/22/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018023
Principal investigator 1 BioNTech SE $195.00 04/22/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018025
Principal investigator 1 BioNTech SE $336.00 04/22/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018061
Principal investigator 1 BioNTech SE $1,784.00 04/22/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018063
Principal investigator 1 BioNTech SE $195.00 04/22/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018065
Principal investigator 1 BioNTech SE $336.00 04/22/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018067
Principal investigator 1 BioNTech SE $1,784.00 04/22/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018069
Principal investigator 1 BioNTech SE $195.00 04/22/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018071
Principal investigator 1 BioNTech SE $97.00 04/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018007
Principal investigator 1 Genentech, Inc. $690.00 04/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579214
Principal investigator 1 Genentech, Inc. $10,880.00 04/15/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579218
Principal investigator 1 BioNTech SE $13,924.00 04/10/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018003
Principal investigator 1 BioNTech SE $690.00 04/10/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018005
Principal investigator 1 BioNTech SE $90.00 04/10/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018009
Principal investigator 1 BioNTech SE $559.00 04/10/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018011
Principal investigator 1 BioNTech SE $138.00 04/10/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018013
Principal investigator 1 BioNTech SE $90.00 04/10/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018045
Principal investigator 1 BioNTech SE $90.00 04/10/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018047
Principal investigator 1 BioNTech SE $13,924.00 04/01/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017999
Principal investigator 1 BioNTech SE $690.00 04/01/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018001
Principal investigator 1 Genentech, Inc. $232.00 04/01/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579202
Principal investigator 1 Genentech, Inc. $104.00 04/01/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579206
Principal investigator 1 Genentech, Inc. $311.00 04/01/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579222
Principal investigator 1 Genentech, Inc. $349.00 04/01/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579231
Principal investigator 1 BioNTech SE $8,905.30 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017913
Principal investigator 1 BioNTech SE $614.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017985
Principal investigator 1 BioNTech SE $1,068.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017987
Principal investigator 1 BioNTech SE $90.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017989
Principal investigator 1 BioNTech SE $173.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017991
Principal investigator 1 BioNTech SE $930.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017993
Principal investigator 1 BioNTech SE $918.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017995
Principal investigator 1 BioNTech SE $59.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017997
Principal investigator 1 BioNTech SE $90.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018043
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,864.00 03/25/2025 Non-covered Recipient Entity
BEVERLY HILLS CANCER CENTER
A phase II multicenter open label two cohort non comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant hormone receptor HR positive HER2 negative advanced breast cancer aBC who have p No dispute reported 06/30/2026 1190308788
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,007.90 03/19/2025 Non-covered Recipient Entity
BEVERLY HILLS CANCER CENTER
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185542442
Principal investigator 1 BioNTech SE $7,851.75 03/14/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017911
Principal investigator 1 BioNTech SE $3,003.90 03/11/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017909
Principal investigator 1 Genentech, Inc. $311.00 03/11/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579161
Principal investigator 1 Genentech, Inc. $479.50 03/11/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579170
Principal investigator 1 Genentech, Inc. $231.92 03/11/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579182
Principal investigator 1 Genentech, Inc. $566.00 03/11/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579185
Principal investigator 1 Genentech, Inc. $208.00 03/06/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579157
Principal investigator 1 Genentech, Inc. $311.00 03/06/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579174
Principal investigator 1 Genentech, Inc. $10,880.00 03/06/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579178
Principal investigator 1 Genentech, Inc. $690.00 03/06/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579189
Principal investigator 1 Genentech, Inc. $347.92 03/06/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579193
Principal investigator 1 Genentech, Inc. $52.00 03/06/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579198
Principal investigator 1 BioNTech SE $8,780.85 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017907
Principal investigator 1 BioNTech SE $345.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017961
Principal investigator 1 BioNTech SE $357.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017963
Principal investigator 1 BioNTech SE $310.50 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017965
Principal investigator 1 BioNTech SE $1,262.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017967
Principal investigator 1 BioNTech SE $497.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017969
Principal investigator 1 BioNTech SE $586.50 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017971
Principal investigator 1 BioNTech SE $656.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017973
Principal investigator 1 BioNTech SE $59.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017975
Principal investigator 1 BioNTech SE $90.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017977
Principal investigator 1 BioNTech SE $150.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017979
Principal investigator 1 BioNTech SE $629.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017981
Principal investigator 1 BioNTech SE $930.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017983
Principal investigator 1 BioNTech SE $90.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018039
Principal investigator 1 BioNTech SE $90.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018041
Principal investigator 1 Genentech, Inc. $1,860.00 03/04/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579166
Principal investigator 1 BioNTech SE $7,976.20 02/18/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017905
Principal investigator 1 BioNTech SE $1,035.00 02/13/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017949
Principal investigator 1 BioNTech SE $90.00 02/13/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017951
Principal investigator 1 BioNTech SE $1,386.00 02/13/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017953
Principal investigator 1 BioNTech SE $838.00 02/13/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017955
Principal investigator 1 BioNTech SE $13,924.00 02/13/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017957
Principal investigator 1 BioNTech SE $690.00 02/13/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017959
Principal investigator 1 BioNTech SE $90.00 02/13/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018033
Principal investigator 1 BioNTech SE $90.00 02/13/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018035
Principal investigator 1 BioNTech SE $90.00 02/13/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018037
Principal investigator 1 BioNTech SE $12,269.25 02/05/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017903
Principal investigator 1 Genentech, Inc. $14,248.00 02/05/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211579226
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,522.75 01/31/2025 Non-covered Recipient Entity
BEVERLY HILLS CANCER CENTER
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) No dispute reported 06/30/2026 1185542440
Principal investigator 1 Novartis Pharmaceuticals Corporation $847.86 01/31/2025 Non-covered Recipient Entity
BEVERLY HILLS CANCER CENTER
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190307253
Principal investigator 1 BioNTech SE $7,976.20 01/21/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017901
Principal investigator 1 BioNTech SE $345.00 01/17/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017933
Principal investigator 1 BioNTech SE $131.10 01/17/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017935
Principal investigator 1 BioNTech SE $1,765.02 01/17/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017937
Principal investigator 1 BioNTech SE $310.50 01/17/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017939
Principal investigator 1 BioNTech SE $463.68 01/17/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017941
Principal investigator 1 BioNTech SE $1,083.30 01/17/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017943
Principal investigator 1 BioNTech SE $930.00 01/17/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017947
Principal investigator 1 BioNTech SE $131.10 01/17/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018027
Principal investigator 1 BioNTech SE $11,909.20 01/17/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018095
Principal investigator 1 AstraZeneca UK Limited $576,284.10 01/14/2025 Non-covered Recipient Entity
BEVERLY HILLS CANCER CENTER
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 No dispute reported 06/30/2026 1185542438
Principal investigator 1 BioNTech SE $483.00 01/09/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017915
Principal investigator 1 BioNTech SE $138.00 01/09/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017917
Principal investigator 1 BioNTech SE $90.00 01/09/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017919
Principal investigator 1 BioNTech SE $150.00 01/09/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017921
Principal investigator 1 BioNTech SE $842.00 01/09/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017945
Principal investigator 1 BioNTech SE $138.00 01/09/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018029
Principal investigator 1 BioNTech SE $90.00 01/09/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018031
Principal investigator 1 BioNTech SE $2,451.08 01/07/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017923
Principal investigator 1 BioNTech SE $463.68 01/07/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017925
Principal investigator 1 BioNTech SE $90.00 01/07/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017927
Principal investigator 1 BioNTech SE $680.00 01/07/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017929
Principal investigator 1 BioNTech SE $150.00 01/07/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249017931
Principal investigator 1 BioNTech SE $8,592.75 01/07/2025 Non-covered Recipient Entity
BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC
BNT327-02 No dispute reported 06/30/2026 1249018093